Pfizer completes acquisition of Swiss biotech Therachon

Pfizer has completed its acquisition of Swiss biotech Therachon in a deal worth up to $810 million.

As per the terms of the deal, Pfizer has paid $340 million up front with an additional $470 million in additional payments dependent on achieving certain key milestones in the development and commercialisation of TA-46.

TA-46 is an investigational medicine for the treatment of achondroplasia, a genetic condition and the most common form of short-limb dwarfism.

There are currently no approved treatment options for achondroplasia.

“Therachon becoming part of Pfizer is representative of our Rare Disease team’s 30-year commitment to develop innovative medicines that address significant unmet medical needs of people with rare diseases,” said Seng Cheng, Senior Vice President and Chief Scientific Officer of Pfizer’s Rare Disease Research Unit.

He added that TA-46 has “the potential to be a first-in-class therapy for the treatment of achondroplasia”.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Novavax selects PolyPeptide to manufacture critical component of COVID-19 vaccine

Novavax has selected CDMO PolyPeptide Group to manufacture a critical component of its novel coronavirus vaccine candidate, NVX-CoV2373. NVX-CoV2373 is a stable, prefusion protein made...

COVID-19 could hinder blockchain implementation in pharma supply chains

Even though blockchain stands out as a potential solution to improve pharma supply chains, COVID-19 may become a hindrance rather than a trigger in...

Emergent joins partnership for COVID-19 vaccine development & manufacturing

Emergent BioSolutions has been issued a task order under an existing contract with the Biomedical Advanced Research and Development Authority (BARDA) to deploy its...

Brilinta approved in US to reduce the risk of first heart attack or stroke

AstraZeneca’s Brilinta (ticagrelor) has been approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with...

GSK to manufacture 1bn doses of pandemic vaccine

GlaxoSmithKline (GSK) is aiming to manufacture one billion doses of its pandemic vaccine adjuvant system, in 2021, to support the development of multiple adjuvanted...

Related news

In brief: New head of R&D for Cellbox Solutions

Germany’s Cellbox Solutions has appointed Lonza Pharma and Biotech’s former Head of Biosolutions R&D as its new Head of R&D. Dr Herbert A. Mueller-Hartmann will...

Novavax selects PolyPeptide to manufacture critical component of COVID-19 vaccine

Novavax has selected CDMO PolyPeptide Group to manufacture a critical component of its novel coronavirus vaccine candidate, NVX-CoV2373. NVX-CoV2373 is a stable, prefusion protein made...

COVID-19 could hinder blockchain implementation in pharma supply chains

Even though blockchain stands out as a potential solution to improve pharma supply chains, COVID-19 may become a hindrance rather than a trigger in...

Emergent joins partnership for COVID-19 vaccine development & manufacturing

Emergent BioSolutions has been issued a task order under an existing contract with the Biomedical Advanced Research and Development Authority (BARDA) to deploy its...